Abbott Shows Earnings Strength
By Zacks Investment Research on October 16, 2008 | More Posts By Zacks Investment Research | Author's Website
Abbott Laboratories (ABT) again beat both consensus of $0.77 and our EPS estimate of $0.76 for the third quarter with EPS of $0.79. We continue to rate shares of Abbott Labs a Buy on the belief that earnings will grow at a CAGR [compound annual growth rate] of almost 12% over the next five years. Strong sales are driven by leading product Humira, an anti-inflammatory for rheumatoid arthritis and psoriasis.
Abbott offers potentially the strongest combination of growth and relative risk in all of the large-cap pharma space. Several new drug applications have recently been filed with the FDA which should accelerate sales in the pharmaceutical business. Based on our model, the company is expected to deliver double-digit EPS growth through the end of 2012. We believe Abbott possesses a low risk profile and will continue to trade at an industry premium.
Abbott currently trades at 16.2x our 2008 EPS estimate of $3.34. While considerably more expensive than the peer average of 11.1x, we believe the premium is warranted. Based on Abbott’s strong line-up of current products along with its formidable pipeline, we believe there is further room for the multiple to expand. We recommend investors purchase the name for a long-term hold within the pharmaceutical / medical sector. Our price target is $65, or 19.5x 2008 EPS estimate of $3.34.
Jason Napodano, CFA, contributed to the report.
Month To Date Market Review
Stock Picks For Monday: Citigroup, JDS Uniphase And General Electric
US Unemployment Rate Troubling, But …
S&P 500: Market Is Strong, But Correction Should Continue
Doctor Up Your Portfolio With This Medical Communications Company
Macedonia’s Jan.-Sept. Trade Deficit At US$1.61 Bln - 1 day ago
Natural Gas Prices Extend Two-Month Low - 1 day ago
Stocks Finish Modestly Higher Despite Weak Jobs Report - U.S. Commentary - 1 day ago
Treasury Economist: Unemployment Numbers Disappointing But Not Unexpected - 1 day ago
Consumer Credit Fell By $14.8 Bln In September - 1 day ago


